M&A Deal Summary

Teva Pharmaceutical Industries Acquires Allergan Generics

On July 27, 2015, Teva Pharmaceutical Industries acquired life science company Allergan Generics from Allergan for 40.5B USD

Acquisition Highlights
  • This is Teva Pharmaceutical Industries’ 18th transaction in the Life Science sector.
  • This is Teva Pharmaceutical Industries’ largest (disclosed) transaction.
  • This is Teva Pharmaceutical Industries’ 12th transaction in the United States.
  • This is Teva Pharmaceutical Industries’ 4th transaction in California.

M&A Deal Summary

Date 2015-07-27
Target Allergan Generics
Sector Life Science
Buyer(s) Teva Pharmaceutical Industries
Sellers(s) Allergan
Deal Type Divestiture
Deal Value 40.5B USD

Target

Allergan Generics

California, United States
Allergan Generics is the generic drugs unit of Allergen Inc.

Search 193,724 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Teva Pharmaceutical Industries

Tel Aviv, Israel

website


Category Company
Founded 1901
Sector Life Science
Employees34,004
Revenue 14.9B USD (2022)
DESCRIPTION

Teva Pharmaceutical Industries is a provider of pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceutical Industries was founded in 1901 and is based in Tel Aviv, Israel.


DEAL STATS #
Overall 19 of 23
Sector (Life Science) 18 of 20
Type (Divestiture) 3 of 4
State (California) 4 of 4
Country (United States) 12 of 15
Year (2015) 2 of 5
Size (of disclosed) 1 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-05-05 Auspex Pharmaceuticals

San Diego, California, United States

Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. It is a developer of innovative medicines for hyperkinetic movement disorders and other rare diseases.

Buy $3.2B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-03 Immuneering

Cambridge, Massachusetts, United States

Immuneering is a trusted advisor to pharmaceutical companies, pioneering new analyses to identify biological insights that improve patients’ lives. Immuneering’s team of experts provides advanced data analysis services using state-of-the-art technologies including proprietary algorithms. The company is a rapidly growing company with seven years of experience analyzing data sets ranging from gene expression (microarray) data, to single-nucleotide polymorphism (SNP) data, to protein concentration data, to clinical metadata, to next-generation sequencing (NGS) data including RNA seq, exome sequencing, and whole-genome sequencing. Using these data sets, Immuneering captures difficult-to-find signals, generates biological hypotheses, and designs follow-up studies, contributing to the development of medicines for patients with a wide range of serious diseases. Immuneering was formed in 2008 and is based in Cambridge, Massachusetts.

Buy -

Seller(S) 1

SELLER

Allergan

Irvine, California, United States

Category Company
Founded 1948
Sector Life Science
Employees11,400
DESCRIPTION

Allergan, Inc. is a pharmaceutical company. Allergan's products include ophthalmic pharmaceuticals, dermatology products, and neurological products.


DEAL STATS #
Overall 3 of 3
Sector (Life Science) 1 of 1
Type (Divestiture) 3 of 3
State (California) 2 of 2
Country (United States) 3 of 3
Year (2015) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-12-02 Allergan - Obesity Intervention Division

Irvine, California, United States

Allergan, Inc. - Obesity Intervention Division is a manufacturer and sells weight loss solutions comprised of the LAP-BAND® adjustable gastric banding system and the ORBERA™ intra-gastric balloon system.

Sell $110M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-10 Oculeve

South San Francisco, California, United States

Oculeve, Inc. is a development-stage medical device company focused on developing novel treatments for dry eye disease.

Buy $125M